Participate in Crown Bioscience's 2023 educational webinar series to expand your knowledge and support your preclinical research and drug development. This series covers various topics, including oncology, immuno-oncology, immune-mediated inflammatory disease, biomarkers, bioinformatics, databases, and more. Register now for our upcoming live webinars, or watch our previous webinars today!
Join us for a pivotal discussion with Mariusz Madej on "Pan-cancer 'Assay-ready' Organoid Drug Screening." With 95% of anticancer drugs failing before clinical stages, Madej highlights a game-changing approach using patient-derived organoids in high-throughput drug screening. These 3D tumor models offer better translatability than traditional 2D cell lines. Delve into a case study on the Assay-ready (AR) organoid platform, which streamlines timelines and costs in drug discovery. Whether you're in research, pharmaceuticals, or keen on cancer treatment advancements, this talk promises transformative insights into the future of cancer drug development.
MS-based proteomics has gained significant traction in translational research, enabling researchers to analyze proteins at an unprecedented level of detail. At Crown Bioscience, we understand the challenges faced in proteomic profiling, especially when it comes to human tumor xenografts, as distinguishing human and mouse proteins in these models can be complex.
Dr. Binchen Mao obtained his M.S. in Biostatistics and Ph.D. in Biochemistry from Rutgers University and has published numerous articles in prestigious journals such as Nature, Nature Methods, JACS, and Structure.
Dr. Mao joined Crown Bioscience in 2016 and currently holds the position of Principal Scientist in the Data Science and Bioinformatics Department. With extensive expertise and work experience in the fields of biostatistics, biomarker analysis, and structural biology, Dr. Mao brings a wealth of professional knowledge to his role.